#United States #New York #Securities Fraud #Pomerantz LLP #Senti Biosciences

Investigation of Senti Biosciences, Inc.

Summary

The Pomerantz Law Firm has recently initiated an investigation concerning allegations of securities fraud regarding Senti Biosciences, Inc. (NASDAQ: SNTI). This action comes shortly after the company's significant stock price decline following critical news regarding its clinical trial for the product SN301A. Investors who believe they may have been affected by this situation are urged to reach out to Danielle Peyton at Pomerantz for more information.

Details of the Investigation

On April 28, 2025, Senti Biosciences announced the suspension of patient enrollment in the Investigator Sponsored Trial for its solid tumor therapeutic candidate SN301A, which had been developed in collaboration with Celes Therapeutics based in Shanghai. The cessation of enrollment was described in the company’s press release as a precautionary measure due to the observation of dose-limiting toxicities during trials. This alarming news had an immediate impact on Senti's stock performance, resulting in a notable drop of $1.36—or 27.2%, closing at $3.64 per share.

Pomerantz LLP's investigation seeks to uncover whether Senti and its management engaged in any unlawful practices that may have misled investors concerning the company's business operations and the potential risks associated with its clinical programs.

About Pomerantz Law Firm

Pomerantz LLP, headquartered in New York and with satellite offices in major cities including Los Angeles, London, and Tel Aviv, is renowned for its focus on corporate, securities, and antitrust class action litigation. The firm has a rich history of representing investors and victims of corporate misconduct, an effort that has earned it a reputation as a leader in the field over its 85 years in operation. Under the vision of its founder, the late Abraham L. Pomerantz, the firm continues to advocate vigorously for shareholder rights.

The firm has successfully recovered millions in damages for class action members, reflecting its commitment to accountability within corporate structures. Individuals who feel they have suffered losses due to Senti's recent disclosures are encouraged to reach out to Pomerantz for assistance in understanding their rights and potential avenues for recourse.

How to Get Involved

Investors looking for more information about the potential class action against Senti Biosciences can make contact with Danielle Peyton at Pomerantz. It’s vital for affected investors to discuss their circumstances and understand how this investigation could pertain to their investment experiences.

In conclusion, with Senti Biosciences facing scrutiny over its handling of trial protocols and communication of risk to investors, stakeholders are advised to keep closely informed and consider their options moving forward as further developments unfold in this ongoing situation.